Sleeping pill claims disturb NAD
This article was originally published in The Tan Sheet
Executive SummaryUrban Nutrition agrees to discontinue certain ad claims for its RestAid dietary supplement, including reference to the product as a "non-prescription sleeping pill," following a NAD review. The decision released Oct. 19, under NAD's CRN-supported work, concludes claims in print and online ads suggesting the product helps consumers fall asleep faster and deeper - and allows them to awake more refreshed - were unsupported by evidence in the record. Rather, NAD recommends limiting such claims to the product's melatonin ingredient. Further, the CBBB division found no evidence to support the claim the product's delivery system "gets the nutrients into the bloodstream much quicker than other supplements." New York-based Urban Nutrition, which agreed to modify its ads, previously was the subject of an Electronic Retailing Self-Regulation Program review that found the firm failed to disclose its material connection to products it endorsed on a review website it operated (1"The Tan Sheet" Aug. 17, 2009, In Brief)
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.